See more : Lithium South Development Corporation (LIS.V) Income Statement Analysis – Financial Results
Complete financial analysis of Adaptive Biotechnologies Corporation (ADPT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Adaptive Biotechnologies Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
- MMI Globale Aktier Akk. – Harding Loevner (MMIGAA.CO) Income Statement Analysis – Financial Results
- Mish Designs Limited (MISHDESIGN.BO) Income Statement Analysis – Financial Results
- RenetJapanGroup,Inc. (3556.T) Income Statement Analysis – Financial Results
- Nishikawa Rubber Co., Ltd. (5161.T) Income Statement Analysis – Financial Results
- Investin – K Invest Globale Aktier II (WEIBGA.CO) Income Statement Analysis – Financial Results
Adaptive Biotechnologies Corporation (ADPT)
About Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 170.28M | 185.31M | 154.34M | 98.38M | 85.07M | 55.66M | 38.45M |
| Cost of Revenue | 75.55M | 57.91M | 49.30M | 22.53M | 22.27M | 19.67M | 15.68M |
| Gross Profit | 94.72M | 127.40M | 105.04M | 75.85M | 62.80M | 36.00M | 22.77M |
| Gross Profit Ratio | 55.63% | 68.75% | 68.06% | 77.10% | 73.82% | 64.67% | 59.22% |
| Research & Development | 122.12M | 141.76M | 142.34M | 116.07M | 70.71M | 39.16M | 32.00M |
| General & Administrative | 83.93M | 88.53M | 74.50M | 49.54M | 30.33M | 20.41M | 15.95M |
| Selling & Marketing | 88.58M | 95.60M | 95.47M | 61.36M | 38.45M | 24.49M | 16.77M |
| SG&A | 172.51M | 184.13M | 169.97M | 110.89M | 68.79M | 44.90M | 32.71M |
| Other Expenses | 27.13M | 1.70M | 1.70M | 1.70M | 1.70M | 1.70M | 1.69M |
| Operating Expenses | 321.76M | 327.59M | 314.01M | 228.67M | 141.19M | 85.75M | 66.40M |
| Cost & Expenses | 397.31M | 385.49M | 363.31M | 251.20M | 163.46M | 105.42M | 82.08M |
| Interest Income | 15.53M | 4.06M | 1.67M | 6.59M | 9.79M | 3.31M | 1.64M |
| Interest Expense | 13.80M | 4.24M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 22.23M | 28.15M | 20.98M | 11.74M | 7.79M | 6.00M | 5.80M |
| EBITDA | -189.27M | -167.98M | -193.35M | -144.35M | -70.60M | -43.76M | -37.84M |
| EBITDA Ratio | -111.16% | -104.92% | -134.29% | -153.60% | -90.15% | -78.61% | -96.23% |
| Operating Income | -227.04M | -200.19M | -208.97M | -152.82M | -78.39M | -49.76M | -44.48M |
| Operating Income Ratio | -133.33% | -108.03% | -135.39% | -155.33% | -92.15% | -89.39% | -115.68% |
| Total Other Income/Expenses | 1.73M | -182.00K | 1.67M | 6.59M | 9.79M | 3.31M | 1.64M |
| Income Before Tax | -225.30M | -200.37M | -207.30M | -146.23M | -68.61M | -46.45M | -42.83M |
| Income Before Tax Ratio | -132.32% | -108.13% | -134.31% | -148.63% | -80.65% | -83.44% | -111.40% |
| Income Tax Expense | 0.00 | -57.90M | -1.69M | -6.59M | -9.79M | 3.31M | -804.00K |
| Net Income | -225.25M | -142.46M | -205.61M | -139.64M | -58.82M | -46.45M | -42.83M |
| Net Income Ratio | -132.29% | -76.88% | -133.22% | -141.93% | -69.14% | -83.44% | -111.40% |
| EPS | -1.56 | -1.00 | -1.46 | -1.06 | -0.85 | -0.44 | -0.41 |
| EPS Diluted | -1.56 | -1.00 | -1.46 | -1.06 | -0.85 | -0.44 | -0.41 |
| Weighted Avg Shares Out | 144.38M | 142.52M | 140.35M | 131.22M | 69.17M | 105.43M | 105.43M |
| Weighted Avg Shares Out (Dil) | 144.38M | 142.52M | 140.35M | 131.22M | 69.17M | 105.43M | 105.43M |
Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting
Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year?
Adaptive Biotechnologies: Making Some Progress
Wall Street Analysts Predict a 31.36% Upside in Adaptive Biotechnologies (ADPT): Here's What You Should Know
Adaptive Biotechnologies Corporation (ADPT) Q3 2024 Earnings Call Transcript
Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Tops Revenue Estimates
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma
Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024
Adaptive Announces IVDR Certification for clonoSEQ® in European Union
Source: https://incomestatements.info
Category: Stock Reports